MANNKIND CORP Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
MANNKIND CORP (MNKD) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 8.47 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2026-08-05
- MANNKIND CORP incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-09-30 was 4.83M shares, a 50.16% decline year-over-year.
- MANNKIND CORP incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-06-30 was 6.53M shares.
- MANNKIND CORP incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-03-31 was 17.42M shares, a 67.97% decline year-over-year.
- MANNKIND CORP incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2024-09-30 was 9.70M shares, a 82.38% decline year-over-year.
- MANNKIND CORP incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2025 was 8.47M shares, a 10.14% decline from fiscal 2024.
- MANNKIND CORP incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2024 was 9.43M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2025-12-31 | 8.47M shares 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 4.83M shares 10-Q · filed 2025-11-05 | 8.25M shares 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | 6.53M shares 10-Q · filed 2026-08-05 | 8.16M shares 10-Q · filed 2025-08-06 | ||
| 2025-03-31 | 17.42M shares 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 9.43M shares 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 9.70M shares 10-Q · filed 2025-11-05 | 8.60M shares 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | 7.65M shares 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 54.38M shares 10-Q · filed 2025-05-08 | |||
| 2023-09-30 | 55.04M shares 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |